Engineered immune cells take aim at multiple myeloma from the start
NCT ID NCT07652138
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new treatment called RN1201 for people newly diagnosed with multiple myeloma, a type of blood cancer. RN1201 uses specially engineered immune cells from a healthy donor to target and kill cancer cells. Participants receive a single infusion of these cells after a short course of chemotherapy. The main goal is to check the safety of this approach and to see how well it controls the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RN1201 (allogeneic CAR-T cells targeting BCMA and CD19)
- What this could lead to
- If successful, this could offer a powerful one-time cell therapy for newly diagnosed multiple myeloma, potentially reducing or eliminating the need for ongoing treatment.
- What could go wrong
- This is a very early, small Phase 1 trial focused on safety, so effectiveness is not yet known. CAR-T therapies can cause serious side effects like cytokine release syndrome and neurological issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYLOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One-shot CAR-T therapy takes on stem cell transplant for multiple myeloma
- New hope for myeloma: experimental drug combo aims to beat standard care
- New drug cocktail shows promise against blood cancer
- 500 myeloma patients to be tracked in Real-World immunotherapy study
- New scan could spot hidden myeloma earlier